Bristol-Myers Squibb’s new MS drug is approved, launch delayed due to COVID-19
Web Hosting

Shares of Bristol-Myers Squibb Co.
bmy
gained 1% in premarket trading on Thursday after the drugmaker said the Food and Drug Administration had approved Zeposia, its oral multiple sclerosis drug. However, the company is delaying the launch of the drug as …
Read More